Atricure announces the first patient treated in the leaaps™ clinical trial

Mason, ohio--( business wire )--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced that the first patient was treated in the left atrial appendage exclusion for stroke prevention (leaaps™) clinical trial (nct 05478304). the patient was treated by u.s. co-principal investigator dr. marc gerdisch at franciscan st. francis heart center in indianapolis, indiana.
ATRC Ratings Summary
ATRC Quant Ranking